Related Experiment Video
Updated: Mar 2, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Prevention of Stroke by Antithrombotic Therapy in Patients with Atrial Fibrillation
Athanasios J Manolis1, Leonidas E Poulimenos2
1Director, Department of Cardiology, Asklepeion, Voula General Hospital, Adjunct Professor of Cardiology, Emory University, Atlanta GA, Adj. Assistant Professor of Hypertension, Boston University, Boston MA.
Insights
Atrial Fibrillation (AF) increases stroke risk, necessitating stroke risk scores like CHADS-VASc and bleeding risk assessments like HAS-BLED. Novel anticoagulants offer alternatives to warfarin, but raise new clinical questions.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial Fibrillation (AF) is a prevalent cardiac arrhythmia linked to significant stroke risk.
- Stroke risk stratification is crucial for guiding antithrombotic therapy in AF patients.
- Balancing stroke prevention with bleeding risk is a key clinical challenge.
Purpose of the Study:
- To review current strategies for stroke risk assessment in AF.
- To discuss the role of bleeding risk scores in guiding antithrombotic therapy.
- To examine the evolving landscape of anticoagulation in AF, including novel agents.
Main Methods:
- Review of established stroke risk scores (CHADS 2, CHADS 2-VASc).
- Evaluation of bleeding risk assessment tools (HAS-BLED).
- Analysis of clinical trial data comparing warfarin with novel oral anticoagulants (NOACs).
Main Results:
- CHADS 2-VASc is a validated tool for stroke risk prediction in AF.
- HAS-BLED score aids in assessing and managing bleeding risk.
- Novel anticoagulants demonstrate efficacy and safety, offering advantages over warfarin.
- Warfarin remains a standard but has limitations addressed by newer agents.
Conclusions:
- Effective stroke risk stratification and bleeding risk assessment are essential in AF management.
- Novel anticoagulants represent a significant advancement in AF treatment, though further research is needed.
- Optimizing antithrombotic therapy requires careful consideration of individual patient risk profiles.
Abstract:
Atrial Fibrillation (AF) is the most common clinically significant sustained cardiac arrhythmia, a major risk factor for strokes whether it is symptomatic or silent. The older CHADS2 score and the newer CHADS2-VASc are well validated to determine stroke risk and guide initiation of antithrombotic therapy, but haemorrhagic risk has to be respected as well, and scores such as HAS-BLED should be widely used. Old fashioned warfarin became standard of care outperforming antiplatelets in every trial but novel classes of anticoagulants that overcome many of warfarin drawbacks have been introduced and are already guideline recommended regiments. Nevertheless their use poses new questions that have to been answered in the near future.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:23Atherosclerosis IV: Nursing Management
01:26Atherosclerosis III: Management
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...